Elizabeth J. Davis

11.5k total citations
64 papers, 1.5k citations indexed

About

Elizabeth J. Davis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Elizabeth J. Davis has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Elizabeth J. Davis's work include Sarcoma Diagnosis and Treatment (22 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Elizabeth J. Davis is often cited by papers focused on Sarcoma Diagnosis and Treatment (22 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Elizabeth J. Davis collaborates with scholars based in United States, United Kingdom and Spain. Elizabeth J. Davis's co-authors include Douglas B. Johnson, Mingxiang Liang, Cai Xiaoning, Dale R. Gardner, Jeffrey A. Sosman, Yajun Wu, Fei Ye, Sunandana Chandra, Daniel Wang and Kristin Kathleen Ancell and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Elizabeth J. Davis

59 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth J. Davis United States 17 740 403 324 281 217 64 1.5k
Qifeng Chen China 22 346 0.5× 523 1.3× 323 1.0× 70 0.2× 233 1.1× 83 1.4k
Lei Fan China 23 257 0.3× 587 1.5× 115 0.4× 111 0.4× 138 0.6× 66 1.3k
Jason Yongsheng Chan Singapore 19 403 0.5× 500 1.2× 213 0.7× 41 0.1× 89 0.4× 107 1.2k
Sung‐Hoon Jung South Korea 25 874 1.2× 616 1.5× 205 0.6× 44 0.2× 550 2.5× 161 2.0k
Qing Zhou China 19 487 0.7× 350 0.9× 203 0.6× 32 0.1× 241 1.1× 62 1.1k
Ming-Ming He China 18 634 0.9× 314 0.8× 315 1.0× 34 0.1× 129 0.6× 49 1.3k
Yue Yu China 22 382 0.5× 600 1.5× 312 1.0× 32 0.1× 316 1.5× 110 1.7k
Shulin Yu China 13 495 0.7× 973 2.4× 165 0.5× 29 0.1× 158 0.7× 18 1.7k
Shintaro Hirata Japan 29 407 0.6× 407 1.0× 483 1.5× 34 0.1× 457 2.1× 161 2.5k
Hong Zhu China 18 437 0.6× 371 0.9× 324 1.0× 35 0.1× 151 0.7× 62 1.3k

Countries citing papers authored by Elizabeth J. Davis

Since Specialization
Citations

This map shows the geographic impact of Elizabeth J. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth J. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth J. Davis more than expected).

Fields of papers citing papers by Elizabeth J. Davis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth J. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth J. Davis. The network helps show where Elizabeth J. Davis may publish in the future.

Co-authorship network of co-authors of Elizabeth J. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth J. Davis. A scholar is included among the top collaborators of Elizabeth J. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth J. Davis. Elizabeth J. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.
2.
Mahalingam, Devalingam, Anwaar Saeed, Steven Powell, et al.. (2025). Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer. ESMO Open. 10(6). 105122–105122. 2 indexed citations
3.
Robinson, Michael J. & Elizabeth J. Davis. (2024). Neoadjuvant Chemotherapy for Adults with Osteogenic Sarcoma. Current Treatment Options in Oncology. 25(11). 1366–1373. 5 indexed citations
4.
Wagner, Andrew J., Jonathan C. Trent, Steven Attia, et al.. (2024). Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. 42(16_suppl). 11533–11533. 1 indexed citations
5.
Salkeni, Mohamad A., Brian Ko, Brian A. Van Tine, et al.. (2023). A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11533–11533. 1 indexed citations
6.
Weiss, Aaron R., Safia K. Ahmed, Wendy Allen‐Rhoades, et al.. (2023). Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group. Journal of Adolescent and Young Adult Oncology. 12(5). 792–793. 1 indexed citations
7.
Dooley, Danielle G., et al.. (2023). Teaching the Teachers: Development and Evaluation of a Racial Health Equity Curriculum for Faculty. MedEdPORTAL. 19. 11305–11305. 10 indexed citations
8.
Bui, Nam Q., Sheima Farag, Angela C. Hirbe, et al.. (2023). A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma. Cancers. 15(9). 2617–2617. 11 indexed citations
9.
Davis, Elizabeth J., et al.. (2023). Palliative care integration for patients on phase I cancer clinical trials. Current Problems in Cancer. 47(5). 101022–101022. 1 indexed citations
10.
Kasper, Bernd, Lorenzo D’Ambrosio, Elizabeth J. Davis, et al.. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. Current Treatment Options in Oncology. 23(3). 439–449. 6 indexed citations
11.
Clark, Joseph I., Brendan D. Curti, Elizabeth J. Davis, et al.. (2021). Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine. 69(4). 888–892. 15 indexed citations
12.
Roy, Amit, Prashant Gabani, Elizabeth J. Davis, et al.. (2021). Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma. Clinical and Translational Radiation Oncology. 27. 114–120. 10 indexed citations
13.
Patrinely, James R., et al.. (2020). Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma. Cancer. 126(15). 3448–3455. 23 indexed citations
14.
Quach, Henry T., et al.. (2019). Health care utilization and steroid‐refractory toxicities from immune checkpoint inhibitors. Cancer. 126(2). 322–328. 14 indexed citations
15.
Davis, Elizabeth J., Joe‐Elie Salem, Arissa Young, et al.. (2019). Hematologic Complications of Immune Checkpoint Inhibitors. The Oncologist. 24(5). 584–588. 115 indexed citations
16.
Davis, Elizabeth J., Douglas B. Johnson, Jeffrey A. Sosman, & Sunandana Chandra. (2018). Melanoma: What do all the mutations mean?. Cancer. 124(17). 3490–3499. 121 indexed citations
17.
Pender, Alexandra, Elizabeth J. Davis, Christina Messiou, et al.. (2018). Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma. Medical Oncology. 35(10). 131–131. 13 indexed citations
18.
Chugh, Rashmi, Kent A. Griffith, Elizabeth J. Davis, et al.. (2015). Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Annals of Oncology. 26(7). 1459–1464. 15 indexed citations
19.
Dhaliwal, Jatinder, et al.. (2011). Healthcare costs and nonadherence among chronic opioid users.. PubMed. 17(1). 32–40. 70 indexed citations
20.
Fiscella, Richard G., Jeff Lee, Elizabeth J. Davis, & John G. Walt. (2009). Cost of Illness of Glaucoma. PharmacoEconomics. 27(3). 189–198. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qifeng Chen Breakdown of academic impact, for papers by Lei Fan Breakdown of academic impact, for papers by Jason Yongsheng Chan Breakdown of academic impact, for papers by Sung‐Hoon Jung Breakdown of academic impact, for papers by Qing Zhou Breakdown of academic impact, for papers by Ming-Ming He Breakdown of academic impact, for papers by Yue Yu Breakdown of academic impact, for papers by Shulin Yu Breakdown of academic impact, for papers by Shintaro Hirata Breakdown of academic impact, for papers by Hong Zhu
Rankless by CCL
2026